diabetic nephropathy. Type 2 diabetes mellitus with diabetic nephropathy
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: patients with DMTII albuminuria more than 30mg/dl
Exclusion criteria
Exclusion criteria: Allergy to valproic acid Significantly abnormal liver function test A history of known mental disorders History of cardiac or liver diseases Females who were lactating, pregnant, or intending to become pregnant during the study. A current history of alcohol addiction or drug abuse including analgesics abnormal blood cells counts eGFR less than 60 ml/min/1.73m2 hemoglobin A1c more than 8 Blood Pressure more than 160/100 mmHg neurologic disease such as seizure use antidepressant or antipsychotic drugs History of GN, renal stone or other renal disease that induced proteinuria active hematologic, rheumatologic or infectious diseases active cancers or tumors uncontrol hypo or hyper thyroidism uncontrol hyper parathyroidism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Microalbuminuria. Timepoint: At the beginning of the study, one month, two months and three months after starting the drug. Method of measurement: Measurement of microalbuminuria of urine samples. | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver function test. Timepoint: At the beginning of the study, one month, two months and three months after starting the drug. Method of measurement: Using the patient's blood sample.;Complete blood count. Timepoint: At the beginning of the study, one month, two months and three months after starting the drug. Method of measurement: Using the patient's blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Shiraz University of Medical Sciences